Leukocyte stem cells (Enlivex Therapeutics)

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameLeukocyte stem cells (Enlivex Therapeutics)
Drug Alias NameApoCellAllocetraLeukocyte stem cell therapy (Enlivex Therapeutics)Allocetra-OTSOTS-Allocetra +[6] 
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derived
Mechanisms of ActionStem cell replacementsImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Community Acquired PneumoniaSolid tumours +[16] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesPoland +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesHadassah Medical OrganizationEnlivex Therapeutics LtdKaplan Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesSheba Medical CenterEnlivex Therapeutics LtdKaplan Medical Center
Inactive CompaniesEnlivex Therapeutics R&D LtdHadassah Medical Organization
Active IndicationsCommunity Acquired PneumoniaCholecystitis, AcuteCholangitis +[8] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursSystemic Inflammatory Response Syndrome +[8] 

Other Information

ATC CodeN/A
Related LinksN/A